Bastian von Tresckow
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Year:
2026
Histopathological growth patterns (GP) in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) have previously been divided into GP AB (typical) vs CDEF (variant). However, it is unclear whether this division is optimal. We thus investigated alternative GP grouping approaches (GP ABC vs DEF; GP ABCF vs DE). Overall, 583 NLPHL patients who had first-line treatment within GHSG trials were included in the analysis. Median age was 39 years; 74% of patients were male; 76% presented with early-stage and 24% with advanced-stage disease. The 5-year and 10-year progression-free survival (PFS) estimates for all patients were 85.9% and 76.6%; overall survival (OS) estimates were 95.8% and 94.5%. Significant PFS and OS differences were detected for the comparison GP ABCF vs DE with worse outcomes for the GP DE group (HR: 1.7; 95%-CI: 1.1–2.7; HR: 2.5; 95%-CI: 1.1–5.7). No PFS and OS differences were observed for the comparisons GP AB vs CDEF and GP ABC vs DEF. Median time to death was shorter and death more often due to NLPHL in the GP DE (13 months; 66.7%) than in the GP ABCF (31 months; 5.6%) group. Hence, the division of GP into GP ABCF vs DE allows an optimized GP-based risk group discrimination in NLPHL.
Year:
2025
Year:
2025
Cellular therapies targeting B-cell maturation antigen have shown promise in controlled clinical trials, but their impact in broader, diverse patient populations remains underexplored. This study examines the real-world efficacy and safety in 343 triple-class–exposed patients with relapsed and refractory multiple myeloma who received idecabtagene vicleucel (ide-cel; n = 266) or ciltacabtagene autoleucel (cilta-cel; n = 77) after >3 previous lines of therapy in Germany. Cilta-cel, compared with ide-cel, demonstrated superior outcomes, achieving a higher overall response rate (94% vs 82%) and 10-month progression-free survival (PFS; 76% vs 47%). Cilta-cel also led to higher complete response (CR; 61% vs 39%) and improved response conversion, with more patients achieving CR after starting from less than CR before chimeric antigen receptor T-cell (CAR T) therapy. For those attaining CR after therapy, cilta-cel showed longer PFS, especially in patients who entered treatment with a partial response or worse. Cytokine release syndrome was observed in 85% of cilta-cel and 81% of ide-cel cases, predominantly low grade. Immune effector cell–associated neurotoxicity syndrome was more common with cilta-cel (25% vs 15%), although nonrelapse mortality at 10 months was comparable between therapies (7% vs 5%). Weighted multivariable analysis after propensity score matching confirmed a significant advantage in terms of PFS for cilta-cel, with a hazard ratio of 0.48. Overall, outcomes in our registry analysis were comparable with the pivotal trials that led to approval of the respective agents. Cilta-cel demonstrated a greater capacity for response conversion and durable remission. These findings underscore the need for individualized CAR T therapy selection to optimize patient outcomes.
Year:
2025
Year:
2025
Objectives The objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior lines of therapy (LoTs; 3L+ R/R DLBCL). Methods We performed an SLR of studies published between 2016 and 2021 and extracted study characteristics, prognostic factors, and EMMs. This was followed by clinical review and ranking of findings by subject matter experts using questionnaires, follow‐up interviews, and quantitative ranking. Results Across 46 included studies, the SLR identified 36 prognostic factors significantly associated with ≥ 1 clinical outcome. Based on subject matter expert ranking of the SLR‐derived list, the five most important prognostic variables in descending order are: early chemo‐immunotherapy failure, Eastern Cooperative Oncology Group performance status, refractory to last LoT, number of prior LoTs, and double‐ or triple‐hit lymphoma. Conclusions This SLR and expert clinical review is the first to provide a comprehensive assessment of prognostic factors for 3L+ R/R DLBCL. No statistically significant EMMs were identified. This robust multi‐method approach can assist in selecting prognostic variables for comparative analyses between real‐world studies and clinical trials.
Year:
2025
Year:
2025
Year:
2025
Table S1 contains the p values of comparisons of the V gene usage in non-malignant GC B cells between the individual genotypes. These comparisons were done on the family, gene and allele level. V usage was compared for all BCR sequences as well as for isotype subsets.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Collaborators (22)
Elena I Rugarli
University of Cologne
Karolin Trautmann-Grill
University Hospital Carl Gustav Carus
Ralf Küppers
Professor
Universität Duisburg-Essen
Christof Scheid
University of Cologne
Gero Knittel
University Hospital Essen
Dennis A. Eichenauer
-
Jan‐Michel Heger
-
Ulrich Keller
Prof. Dr.
Charité - Universitätsmedizin Berlin
Michael Fuchs
University of Cologne
Justin Ferdinandus
University Hospital Bonn
Julia von Tresckow
University Hospital Essen
Graziella Bosco
University of Cologne
Maximilian Merz
Memorial Sloan Kettering Cancer Center
Tomas Jelinek
-
Dinis Calado
Senior Group Leader
Babraham Institute
Reinhard Büttner
Head of Department
University of Cologne
Davide Rossi
Associate Professor of Medicine
Università della Svizzera Italiana (USI)
Bjoern Chapuy
Professoor
Charité - Universitätsmedizin Berlin
Florian Kron
University of Applied Sciences
Thomas Pabst
Professor
University Hospital of Bern
Hans Christian Reinhardt
-
Ari M. Melnick
Director
Josep Carreras Leukaemia Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.